January 2013, Vol 4, No 1

San Diego, CA—Adherence to several quality care standards markedly improved in practices participating in ASCO’s Quality Oncology Practice Initiative (QOPI) over a 4-year period, according to a study presented at ASCO’s inaugural 2012 Quality Care Symposium.
Read Article

Atlanta, GA—Targeting Bruton’s tyrosine kinase (BTK) in patients with chronic lymphocytic leukemia (CLL) resulted in high response rates, without severe toxicity, according to the results of 2 studies that were presented at the 2012 American Society of Hematology meeting.
Read Article

San Antonio, TX—The national cost of screening mammography could vary by as much as $7 billion annually, depending on the screening strategy, according to a new study reported at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium.
Read Article

Atlanta, GA—The new oral tyrosine kinase inhibitor (TKI) ponatinib (Iclusig) has significant activity and is well tolerated in patients with highly pretreated chronic myeloid leukemia (CML) or with Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) who otherwise lack therapeutic options.
Read Article

Page 4 of 4